Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 2,700 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total value of $175,689.00. Following the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,745,429.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Gilead Sciences stock traded down $0.62 during midday trading on Friday, reaching $64.30. The company’s stock had a trading volume of 3,013,983 shares, compared to its average volume of 7,247,871. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $79.61. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The stock has a market cap of $82.40 billion, a PE ratio of 10.46, a P/E/G ratio of 4.07 and a beta of 1.16.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The business’s revenue was down 2.6% on a year-over-year basis. As a group, analysts expect that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date is Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is currently 40.98%.
A number of research analysts recently commented on the company. Wells Fargo & Co cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research report on Monday, February 11th. Raymond James set a $90.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Guggenheim assumed coverage on Gilead Sciences in a research report on Monday, December 17th. They issued a “buy” rating and a $86.00 price target on the stock. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, December 4th. Finally, Citigroup cut Gilead Sciences from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $100.00 to $75.00 in a research report on Tuesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $82.29.
A number of institutional investors have recently added to or reduced their stakes in GILD. Pinnacle Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $48,000. Occidental Asset Management LLC lifted its stake in shares of Gilead Sciences by 7.3% in the fourth quarter. Occidental Asset Management LLC now owns 6,740 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 460 shares during the period. Jackson Hole Capital Partners LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $319,000. Arbor Wealth Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $50,000. Finally, MUFG Securities EMEA plc lifted its stake in shares of Gilead Sciences by 34.4% in the fourth quarter. MUFG Securities EMEA plc now owns 243,280 shares of the biopharmaceutical company’s stock worth $15,217,000 after acquiring an additional 62,257 shares during the period. Hedge funds and other institutional investors own 79.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Director John Francis Cogan Sells 2,700 Shares” was first published by Highlight Press and is the sole property of of Highlight Press. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://highlightpress.com/2019/03/22/gilead-sciences-inc-gild-director-john-francis-cogan-sells-2700-shares.html.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Article: Consumer Price Index (CPI)
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.